TABLE 1.
Demographic characteristics by clinical diagnosis within the CSF cohort and CSF + PET subset
| CSF cohort | CSF + PET subset | |||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic | All | CU | MCI | AD dementia | All | CU | MCI | AD dementia |
| Number of participants | 874 | 727 | 105 | 42 | 524 | 416 | 69 | 39 |
| Cohort study, no. (%) | ||||||||
| MCSA | 804 (92%) | 715 (98%) | 84 (80%) | 5 (12%) | 475 (91%) | 414 (100%) | 54 (78%) | 7 (18%) |
| ADRC | 70 (8%) | 12 (2%) | 21 (20%) | 37 (88%) | 49 (9%) | 2 (0%) | 15 (22%) | 32 (82%) |
| Age (years) | ||||||||
| Median (IQR) | 73 (64, 79) | 72 (63, 79) | 77 (71, 83) | 72 (65, 80) | 71 (63, 78) | 70 (61, 77) | 77 (68, 83) | 72 (64, 80) |
| Range | 32 to 95 | 32 to 95 | 51 to 92 | 50 to 91 | 32 to 95 | 32 to 95 | 51 to 94 | 51 to 88 |
| Male sex, no. (%) | 502 (57%) | 410 (56%) | 66 (63%) | 26 (62%) | 296 (56%) | 229 (55%) | 43 (62%) | 24 (62%) |
| Education (years), median (IQR) | 14 (12, 16) | 14 (12, 16) | 14 (12, 16) | 16 (12, 16) | 14 (12, 16) | 14 (12, 16) | 14 (12, 17) | 16 (12, 16) |
| APOE ε4 carrier, no. (%) | 262 (30%) | 191 (26%) | 41 (39%) | 30 (71%) | 171 (33%) | 117 (28%) | 27 (39%) | 27 (69%) |
| Short Test of Mental Status, Median (IQR) | 35 (33, 37) | 36 (34, 37) | 32 (29, 33) | 26 (21, 28) | 35 (33, 37) | 36 (34, 37) | 32 (29, 34) | 25 (20, 28) |
| Aβ42 (pg/mL), median (IQR) | 1050 (716, 1493) | 1107 (792, 1538) | 847 (602, 1223) | 479 (351, 585) | 1026 (676, 1444) | 1099 (794, 1515) | 764 (490, 1183) | 510 (403, 607) |
| t‐tau (pg/mL), median (IQR) | 220 (168, 289) | 213 (166, 270) | 246 (190, 345) | 318 (254, 467) | 217 (168, 284) | 208 (163, 266) | 244 (187, 302) | 361 (265, 530) |
| p‐tau (pg/mL) median (IQR) | 19 (14, 25) | 18 (14, 23) | 22 (16, 31) | 29 (25, 41) | 19 (14, 25) | 18 (14, 23) | 21 (16, 27) | 32 (26, 47) |
| t‐tau/Aβ42, median (IQR) | 0.18 (0.14, 0.31) | 0.17 (0.14, 0.25) | 0.25 (0.16, 0.54) | 0.79 (0.53, 1.08) | 0.19 (0.14, 0.34) | 0.17 (0.14, 0.25) | 0.26 (0.17, 0.58) | 0.81 (0.52, 1.07) |
| p‐tau/Aβ42, Median (IQR) | 0.015 (0.012, 0.027) | 0.015 (0.012, 0.021) | 0.021 (0.014, 0.049) | 0.069 (0.049, 0.108) | 0.016 (0.012, 0.030) | 0.015 (0.012, 0.021) | 0.021 (0.015, 0.054) | 0.071 (0.049, 0.111) |
| Amyloid PET | ||||||||
| SUVR, median (IQR) | 1.40 (1.33, 1.69) | 1.38 (1.32, 1.50) | 1.60 (1.37, 2.24) | 2.43 (2.23, 2.63) | ||||
| Abnormal, no. (%) | 146 (28%) | 75 (18%) | 35 (51%) | 36 (92%) | ||||
CU = Cognitively Unimpaired, MCI = Mild Cognitive Impairment, AD = Alzheimer's Disease, MSCA = Mayo Clinic Study of Aging, ADRC = Alzheimer's Disease Research Center, IQR = Inter‐quartile Range, AB42 = amyloid‐beta42, t‐tau = total tau, p‐tau = hyperphosphorylated tau, SUVR = Standard Uptake Value Ratio.